smartbax announces a €4.7 M Pre-Series A round to advance novel antibiotic compound through preclinical stage
Globenewswire·2025-10-22 08:00
Lead antibacterial compound against a novel target in Gram-negative bacteria validated in infection modelsProgressing a platform of small-molecule enzymatic activators that induce self-digestion of bacteria as novel mode of action against multi-drug resistant Gram-negative and Gram-positive bacteriaFunding round led by Anobis Asset and Bayern Kapital; second closing remains open Munich, Germany, Oct. 22, 2025 (GLOBE NEWSWIRE) -- smartbax, a biotech company developing next-generation antibiotics against m ...